Foslevodopa/Foscarbidopa Improves Pain in People With Advanced Parkinson’s Disease Who Have Uncontrolled Motor Fluctuations: Interim Results From the Real-World ROSSINI Study (P3-17.006)
The central aim is to assess changes in Parkinson’s disease-related pain following continuous subcutaneous infusion of foslevodopa/foscarbidopa.
Intervention involved 24-hour/day continuous subcutaneous infusion of foslevodopa/foscarbidopa.
Population consists of individuals with advanced Parkinson’s disease and uncontrolled motor fluctuations.
Interim results evaluated the effectiveness of the treatment.
Pain levels significantly decreased after the initiation of treatment, indicating effective pain management.
Specific numerical results are not detailed in the abstract.
Abstract
To evaluate change in Parkinson’s disease (PD)-related pain after initiation of 24-hour/day continuous subcutaneous infusion of foslevodopa/foscarbidopa (LDp/CDp).
KI fragen
Like
Bookmark
Share
View Full Paper
KI fragen
Like
Bookmark
Share
View Full Paper
Foslevodopa/Foscarbidopa Improves Pain in People With Advanced Parkinson’s Disease Who Have Uncontrolled Motor Fluctuations: Interim Results From the Real-World ROSSINI Study (P3-17.006) | Synapse